Extent and cost of inappropriate use of tumour markers in patients with pulmonary disease: a multicentre retrospective study in Shanghai, China

BMJ Open
Haichen ZhangJin Ma

Abstract

The currently implemented healthcare reform in China requires substantial capital investment. Although overtreatment results in serious waste, inappropriate laboratory use is widespread, and overuse of tumour markers (TMs) has attracted increasing attention. Retrospective study. The respiratory, thoracic surgery and oncology departments of three hospitals in Shanghai from 2014 to 2015. Patients with chronic obstructive pulmonary disease (COPD) and primary bronchogenic lung cancer (PLC). Based on clinical guidelines and physician experience, the criteria of suitability of TM examinations were determined, and the number, cost and proportion of inappropriate TM requests were analysed. The area under the receiver operating characteristic curve for carcinoembryonic antigen+cytokeratin fragment 21-1+squamous cell carcinoma antigen+neuron-specific enolase in patients with COPD and PLC was 0.813, in accordance with the cost-effectiveness principle, indicating good clinical and health economics values. In the 2706 patients, 12 496-16 956 (58.27%-79.06%) of TM requests were inappropriate. Furthermore, the involved expense was 650 200-1 014 156 yuan, accounting for 7.69%-12.00% of examination expenses and 1.35%-2.11% of hospitalisation co...Continue Reading

References

Dec 8, 1990·BMJ : British Medical Journal·D Bareford, A Hayling
Apr 15, 2004·Respiratory Medicine·Fabrice BarlésiJean-Pierre Kleisbauer
May 10, 2005·Nursing & Health Sciences·Margareta I K von Bothmer, Bengt Fridlund
Jul 1, 2005·Demography·Anne Case, Christina Paxson
Apr 8, 2006·BMJ : British Medical Journal·Anna BarfordMary Shaw
Mar 12, 2010·The New England Journal of Medicine·Manesh R PatelPamela S Douglas
Mar 16, 2012·JAMA : the Journal of the American Medical Association·Donald M Berwick, Andrew D Hackbarth
Jun 27, 2012·Archives of Internal Medicine·Jerome R Hoffman, Richelle J Cooper
Jun 27, 2012·Annals of Clinical Biochemistry·W S A Smellie
Sep 28, 2012·Journal of Clinical Pathology·Anthony A Fryer, W Stuart A Smellie
Nov 2, 2012·The New England Journal of Medicine·Steven WoloshinBarnett S Kramer
Apr 10, 2013·BMC Medical Informatics and Decision Making·Donald L LevickDavid Pucklavage
May 20, 2014·American Journal of Clinical Pathology·Ronald G Hauser, Brian H Shirts
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott D RamseyDavid L Veenstra
Jan 20, 2015·Scandinavian Journal of Clinical and Laboratory Investigation·Nikolaos BarouchosEleni Bassiakou
May 8, 2015·Chinese Medical Journal·Xiao-Lin Luo, Wei-Yuan Zhang
Mar 10, 2016·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerMiranda Hughes

❮ Previous
Next ❯

Citations

Feb 5, 2021·Frontiers in Neurology·Chiara TrevisiolPatrizia De Massis

❮ Previous
Next ❯

Methods Mentioned

BETA
hysterectomy

Related Concepts

Related Feeds

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.